The Office of Digital Transformation (ODT) provides the vision and leadership in information technology (IT), data, and cybersecurity needed to advance FDA’s...

What is oral immunotherapy for food allergy? Oral immunotherapy (OIT) refers to feeding an allergic individual an increasing amount of an allergen with the goal of increasing the threshold that triggers a reaction. For example, a person allergic to peanuts may be given very small amounts of peanut protein that would not trigger a reaction.

In January 2020, an OIT treatment for peanut allergy received approval from the U.S. Food and Drug Administration (FDA). Palforzia® – developed by Aimmune Therapeutics and previously known as AR101 – is an OIT peanut flour product with known protein content.

Oral immunotherapy is a medical treatment in which an individual who is allergic to a specific food consumes an increasing amount of the allergen with the goal of reducing the risk of...

Peanut oral immunotherapy (OIT) with peanut allergen powder-dnfp (Palforzia ®) is an FDA-approved treatment for children ages 4 to 17 years that can help reduce the risk and severity of allergic reactions to peanuts, including anaphylaxis. The therapy consists of daily exposure to peanut protein powder in increasingly larger doses over a six ...

2025年3月1日 · In the first head-to-head trial comparing Xolair to OIT, the study met its primary endpoint showing 36% of food allergy patients treated with Xolair monotherapy could tolerate at least 2,000 mg of peanut protein (about eight peanuts) and two other food allergens without experiencing an allergic reaction, compared to 19% in the OIT group (odds ...

2025年3月10日 · Today, there is only one FDA-approved OIT treatment (Palforzia), and it only treats peanut allergy. ADP101 is a novel, pharmaceutical-grade OIT candidate from Alladapt Immunotherapeutics intended to treat single or multiple food allergies to 15 common allergenic foods simultaneously.

Peanut oral immunotherapy (OIT) is one of the most investigated alternative options with a recent United States Food and Drug Administration (FDA) approval in early 2020 for a peanut OIT product, Palforzia. In this review, we examine data from peanut OIT clinical trials and discuss the recent trends and future developments in peanut OIT.

Food immunotherapy involves gradual administration of increasing doses or fixed doses of the specific allergen daily with the aim to increase the clinical reaction threshold. Food allergy research groups have studied several different ways to administer immunotherapy, including epicutaneous (EPIT), sublingual (SLIT), and oral (OIT).

The U.S. Food and Drug Administration (FDA) approved the peanut OIT product Palforzia® (formerly known as AR101) in January 2020. The arrival on the market of an FDA-approved OIT product will likely expand the number of physicians willing to try administering OIT to patients.